ArticleClinical epigenetics2026
DNA methylation profiling in Huntington's disease reveals disease associated changes in the striatum.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHuntington's disease is caused by a trinucleotide CAG repeat expansion in the HTT gene. Despite displaying autosomal dominance, phenotypic variation exists amongst mutation carriers, in particular relating to the age that symptoms first occur. This variation is primarily driven by an inverse relationship between CAG expansion size and age of symptom onset. However, the majority of variation in age of onset that is independent of CAG repeat length is thought to be driven by environmental influences. Since DNA methylation can be altered by environmental factors, and as methylomic variation is reported in other neurodegenerative diseases, it may offer a potential mechanism underlying disease manifestation.
resultsWe utilized the Illumina EPIC v1 methylation array to profile DNA methylation in 120 samples, including three distinct brain regions (striatum, entorhinal cortex and cerebellum) in 20 Huntington's disease and 22 control donors. We identified seven Bonferroni-significant differentially methylated CpGs within the striatum along with 27 differentially methylated regions, annotated to genes involved in physiological processes known to be disrupted in HD such as the urea cycle and metabolism. Weighted gene correlation network analysis identified modules of co-methylated CpGs that were associated with Huntington's disease, with ontological analyses showing enrichment in disease relevant processes. Furthermore, integration of single-nuclei RNA sequencing data highlighted that genes annotated to these modules are enriched in striatal spiny projection neurons, the primary cell types affected in the disease.
conclusionsHere, we present the first epigenome-wide association study of Huntington's disease conducted in the striatum, the primary region of neuropathology, along with matched entorhinal cortex and cerebellum on the Illumina EPIC v1 array. Our results suggest that DNA methylation is altered at loci associated with Huntington's disease in disease relevant regions and cell types and strengthens evidence for areas of potential therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.